抗抑郁药遭质疑(2)【沪江慢速VOA080319】

作者：VOA | 沪江听说VOA美国之音时间：3年前 | 阅读：2908次 | [划词　　　]

Report Points to Limits of Some Antidepressants (2/2)

The two best-known drugs in the study were fluoxetine, better known as Prozac, and paroxetine, sold in the United States under the name Paxil. The other drugs were venlafaxine and nefazodone.
The Public Library of Science published the findings last month in the journal PLoS Medicine.

Benedetto Vitiello is a psychiatrist at the United States National Institute of Mental Health. Doctor Vitiello, who was not involved in the study, says the findings came as no great surprise. He says psychiatrists have known for years that S.S.R.I.s work best in the sickest patients. But he says it is important for people who need help not to delay seeking help as a result of the new report.

Critics of the report say S.S.R.I.s can take more time to begin working than the studies permitted. They also note that doctors sometimes try several antidepressants on a patient before choosing one for treatment.

Future antidepressants might have targets other than serotonin. Scientists funded by the National Institute of Mental Health have found that an enzyme called GSK3B might play a big part in depression. They found that mice with low serotonin levels and signs of depression improved when the enzyme was blocked.

参考译文：

这个研究中最著名的两种药品就是氟西汀，也被称为百忧解，以及帕罗西汀，在美国的被称为赛乐特。另外还有文拉法辛和法唑酮盐酸盐。

科学公共图书馆上个月在《科学公共图书馆医学》期刊上发表了这些结果。

Benedetto Vitiello是美国精神健康研究所的精神病学家。Vitiello医生并没有参加此次研究，他说研究结果并不令人吃惊，因为精神病学家早就知道选择性再摄取抑郁剂对于病情严重的病人最有疗效。不过他说需要帮助的人千万不要因为新的报告而延迟寻找帮助。

报告的评论家说选择性再摄取抑郁剂比研究上所说的见效时间更长，他们还说医生通常会给病人用几种不同的抗抑郁剂，然后再选择一种用来治疗。

除了5-羟色胺之外，将来的抗抑郁药可能会有不同的靶点。由美国精神健康研究所所资助的科学家们发现一种叫做GSK3B的酶在抑郁症中起了很大作用。他们发现那些5-羟色胺水平较低的小鼠，当它们体内的这种酶被阻断后，抑郁现象有所好转。